Eton Pharmaceuticals to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025
Eton Pharmaceuticals (Nasdaq: ETON) announced it will report third quarter 2025 financial results on Thursday, November 6, 2025.
Rhea-AI Summary
Eton Pharmaceuticals (Nasdaq: ETON) announced it will report third quarter 2025 financial results on Thursday, November 6, 2025. Management will host a conference call and live audio webcast at 4:30 p.m. ET (3:30 p.m. CT) to discuss results and take live and emailed investor questions.
Investors may submit questions to investorrelations@etonpharma.com. The live webcast is available on the company investor website at https://ir.etonpharma.com/. An archived webcast will be posted approximately two hours after the event and remain available for 30 days.
Positive
- None.
Negative
- None.
Details
News Market Reaction – ETON
On Oct 24, the first trading day after this news, ETON closed 0.43% below the previous close.
Data tracked by StockTitan Argus for the Oct 24 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
DEER PARK, Ill., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report third quarter 2025 financial results on Thursday, November 6, 2025. Management will host a conference call and live audio webcast to discuss the results at 4:30 p.m. ET (3:30 p.m. CT).
| Participant Call Link: | Click Here |
| Webcast: | Click Here |
In addition to taking live questions from participants on the conference call, management will be answering emailed questions from investors. Investors can email questions to: investorrelations@etonpharma.com.
The live webcast can also be accessed on the Investors section of Eton’s website at https://ir.etonpharma.com/. An archived webcast will be available on Eton’s website approximately two hours after the completion of the event and for 30 days thereafter.
About Eton Pharmaceuticals
Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company currently has eight commercial rare disease products: KHINDIVI™, INCRELEX®, ALKINDI SPRINKLE®, GALZIN®, PKU GOLIKE®, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has five additional product candidates in late-stage development: ET-600, Amglidia®, ET-700, ET-800 and ZENEO® hydrocortisone autoinjector. For more information, please visit our website at www.etonpharma.com.
Investor Relations:
Lisa M. Wilson
In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com
Source: Eton Pharmaceuticals, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.